Evolving perspectives on clopidogrel in the treatment of ischemic stroke

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Background:

• Antiplatelet therapy is crucial for managing ischemic stroke and transient ischemic attack (TIA).
• Aspirin is a primary treatment, reducing vascular events by approximately 25%.
• Clopidogrel has been investigated to further mitigate risks in these patients.

Purpose of the Study:

• To evaluate the efficacy and safety of clopidogrel, alone or in combination with aspirin, for secondary prevention in patients with ischemic stroke or TIA.
• To compare combination therapy (aspirin plus clopidogrel) against monotherapy (aspirin or clopidogrel alone).

Main Methods:

• Analysis of clinical trial data, including the Management of Atherothrombosis with Clopidogrel in High-risk Patients and Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trials.
• Comparison of outcomes between combination antiplatelet therapy and single-agent therapy.

Main Results:

• Combination therapy with aspirin and clopidogrel did not demonstrate a significant incremental benefit over aspirin or clopidogrel monotherapy.
• The combination therapy was associated with an increased risk of serious bleeding events.
• Clopidogrel monotherapy showed efficacy in reducing vascular events.

Conclusions:

• For long-term treatment of ischemic stroke or TIA survivors, dual antiplatelet therapy with aspirin and clopidogrel offers no significant advantage over single therapy.
• Clopidogrel serves as an effective alternative antiplatelet agent for patients who cannot tolerate aspirin.
• Risk-benefit assessment favors single antiplatelet therapy unless specific indications for dual therapy exist.